Oxford Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Oxford Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-18,700	Closed	-$164K	–	1767
2018 Q3	$164K	Sell	18,700 -18,307	-49%	-$152K	﹤0.01%	1619
2018 Q2	$326K	Sell	37,007 -7,993	-18%	-$51.8K	0.01%	1469
2018 Q1	$248K	Buy	45,000 +25,863	+135%	+$178K	0.01%	1448
2017 Q4	$156K	Buy	+19,137	New	+$172K	﹤0.01%	1487

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Oxford Asset Management's ARCT Position: Q4 2018 in Review

Oxford Asset Management sold out of Arcturus Therapeutics (ARCT) in Q4 2018, closing a stake of 18,700 shares — an estimated $164K sold.

Oxford Asset Management first reported a position in ARCT in Q4 2017 and held it in 4 quarters. The position peaked at $326K in Q2 2018. 19 funds tracked by Wall St. Rank hold ARCT as of Q4 2018.

Oxford Asset Management reported no remaining Arcturus Therapeutics position as of Q4 2018 after selling out during the quarter.
Oxford Asset Management sold 18,700 Arcturus Therapeutics shares in Q4 2018, an estimated $164K.
Oxford Asset Management first reported a position in Arcturus Therapeutics in Q4 2017 and held it in 4 quarters.
Oxford Asset Management's Arcturus Therapeutics position peaked at $326K in Q2 2018.
19 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2018.

Based on Oxford Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.